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 What is already known: 
• Type 2 diabetes is a chronic disease in which treatment targets in regard to 
glycaemic control, blood pressure, and lipids in combination are often not achieved 
in real life practice.  
• RCTs  have shown the superiority of bariatric surgery compared to medical 
treatment in patients with Type 2 diabetes 
• Trials assessing the impact of Laparoscopic Adjustable Gastric Banding (LAGB) were 
of up to 3 years duration and mainly focussed on the impact of surgery on weight 
and glycaemic control.  
 What this study adds: 
• The impact of LAGB and multidisciplinary care on patients with type 2 diabetes and 
obesity in real life setting with an average of 5 years follow up 
• LAGB combined with multidisciplinary care results in significant improvements in 
weight, glycaemic control, blood pressure and lipids that were sustained over the 5 
years period despite reduction in the use of insulin treatment. 
• Higher pre-operative glycosylated haemoglobin was associated with greater 
improvements in glycaemic control post operatively. Higher pre-operative body mass 
index did not predict changes in glycaemic control, Blood pressure or lipids after 
LAGB 
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 Abstract 
Aims 
The long-term outcomes of weight loss maintenance induced by Laparoscopic Adjustable 
Gastric Band followed (LAGB) by multidisciplinary medical care in patients with type 2 
diabetes mellitus (T2DM) (beyond 3 years) are scarcely reported. Study aims were to 
determine the longer term metabolic outcomes following LAGB combined with medical care 
in patients with T2DM.  Methods 
A longitudinal analysis of 200 adults with T2DM who had LAGB between 2003 and 2008 and 
were followed-up till 2013 at a single bariatric unit in a tertiary UK centre.  Results  
Two-hundred patients (age 47±9.7 years, body mass index (BMI) 52.8±9.2 Kg/m2, 
glycosylated haemoglobin (HbA1c) 7.9±1.9 % (62.8 mmol/mol), women n=123 (61.5%), 
insulin treatment n=71 (35.5%)) were included. The mean follow-up was 62.0 ± 13.0 months 
(range 18 to 84 months).  There were significant reductions in body weight (- 24.4% ± 12.3% 
(38 ± 22.7kg)), HbA1c (- 1.4± 2.0 %), systolic blood pressure (BP) (-11.7±23.5 mmHg), total 
cholesterol and triglyceride levels. The proportion of patients requiring insulin reduced from 
36.2% to 12.3%. The overall band complication rate was 21% (21 patients).  Conclusions 
LAGB when combined with multidisciplinary medical care significantly improved metabolic 
outcomes in patients with T2DM independent of diabetes duration, and baseline BMI over 5 
years. Diabetes duration and baseline BMI did not predict changes in glycaemic control, BP 
or lipids following LAGB. 
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 Introduction  
The impact of bariatric surgery in patients with Type 2 diabetes mellitus (T2DM) has 
attracted increasing attention(1-3). Several studies showed that laparoscopic adjustable 
gastric banding (LAGB) was superior to medical treatment in patients with T2DM in terms of 
weight loss, and glycaemic control, and that LAGB was associated with favourable impacts 
on retinopathy and chronic kidney disease(4-7). Nonetheless, the longer term outcomes of 
weight loss maintenance following LAGB in patients with T2DM (beyond 3 years) are 
scarcely reported.  Furthermore, there is limited evidence assessing the impact of long-term 
weight loss following LAGB on lipids and blood pressure (BP) in patients with T2DM. Studies 
have shown that patients randomised to LAGB achieved greater diabetes remission and 
greater HbA1c reductions compared to medical care (33% of patients undergoing LAGB 
reached the target HbA1c level below 6.5% at one year, compared to 23% in the medically 
managed cohort; 12 patients reaching diabetes remission at 2 years compared to 2 patients 
in the medically treated group)(8, 9). There is limited ‘real life’ data available in the literature 
about the effect of LAGB combined with a multi-disciplinary team (MDT) approach on the 
management of this group of patients(10). Therefore there is a need to assess the impact of 
LAGB combined with MDT care on a large heterogeneous group of patients with T2DM over 
a longer period of time.  
 
Our primary aim was to determine the longer term metabolic outcomes following LAGB 
combined with medical care in patients with T2DM. A secondary outcome was to assess the 
predictors of change in the above-mentioned metabolic parameters.  
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 Methods 
We conducted a longitudinal analysis of patients with T2DM who received LAGB at a single 
tertiary bariatric centre between 2003 and 2008. Of 1815 patients, 200 patients (11.01%) 
had a diagnosis of T2DM with a minimum of one year of follow-up and were included. Data 
was prospectively collected on a yearly basis till 2013 using the hospital’s electronic patient 
records and from the primary care physicians’ when needed. Pre-operation assessment was 
carried out within 6 weeks of the date of surgery. It was at this point that blood samples 
were taken therefore these results were taken as baseline markers. For weight and blood 
pressure the baseline value was the date of surgery. The last available clinical observation 
was included in the analysis. 
 
Patients were considered to have T2DM if they either had a physician diagnosis, a HbA1c >= 
6.5%, a fasting plasma glucose of ≥7.0mmol/L or random plasma glucose of ≥11.1mmol/L 
with symptoms or on two occasions without symptoms(11). Hypertension was defined as a 
known history of hypertension, the use of anti-hypertensive medication at baseline, or if the 
patient was found to have a persistently raised BP above 140/90mmHg(12). 
 
Surgical procedures and post-operative management: Procedures were performed by a 
single surgical team with standard technique previously described(13). Three different bands 
were used over the study period (Allergan Vanguard®TM, Allergan AP large®TM and Swedish 
bands®TM). Patients underwent the same standard peri-operative, and postoperative 
management. For follow-up, patients were seen at 6 weeks, 3 months, 6 months, 6 monthly 
until 2 years, and then annually or on request. Patients had fluoroscopy-guided bands 
adjustments at 3 and 6 months and thereafter as required. The multidisciplinary team 
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(MDT) included surgeons, dieticians, radiologists and physicians. MDT meetings were 
scheduled weekly. Patients were discussed in the MDT at the request of the health care 
professional (HCP) who had contact with the patient. There were a variety of reasons for 
which patients were discussed in the MDT including: excessive or inadequate weight loss at 
the discretion of the HCP, gastrointestinal symptoms, concerns regarding metabolic control 
at the discretion of the HCP or the patient, disordered eating, or the patients’ request. The 
MDT discussed different management options such as dietary modifications, addressing 
specific behavioural issues, band fills/adjustment and optimisation of the medical 
management. Following the MDT decision, the appropriate management plan was initiated 
with the involvement of the appropriate speciality(ies) as required. MDT decisions regarding 
the management of glycaemic control and cardiovascular risk factors were implemented 
either via the primary care physician, or the treating physician or Weight management 
specialist depending on the clinical situation. 
 
The analysis was performed as part of health service evaluation assessing the outcomes of 
LAGB at our centres and hence ethical approval was not required. 
 
Statistical methods: Analysis was performed using Statistical Package for Social Sciences 22 
(SPSS® Chicago, IL). Data were expressed as mean and standard deviation (SD) and ranges or 
frequencies depending on data distribution. Weight loss was described as absolute BMI loss, 
total body loss and as percentage excess BMI loss(14). To assess the impact of LAGB on the 
metabolic parameters, data were presented on yearly basis and the differences between 
baseline and study-end were assessed using the paired t test or the Wilcoxon signed ranks 
test depending on data distribution. The latest available follow-up measurement was 
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inserted as the study-end value. For missing data we have performed a sensitivity analysis 
using the baseline observation carried forward method as this is likely to represent worst 
case scenario, i.e. no change in any of the measured outcomes after LAGB. We have also 
performed a sensitivity analysis in a subgroup of study participants who are confirmed to 
still have the LAGB at study-end. The follow-up duration for any of the particular outcome 
measures was defined as the time between baseline measurements and the final available 
measurement.  
 
To assess predictors of changes in HbA1c, BP, lipids and weight multiple linear regressions 
were used. The outcome measure was the change in the metabolic parameter of interest. 
The independent variables included demographics, baseline values of the outcome 
measure, other factors that are biologically related to the outcome measure and the 
duration of follow-up for the particular outcome measure. The enter method was used in all 
the regression models. All linear regression assumptions were adhered to.  We assessed the 
weight loss across quartiles of HbA1c change post bariatric surgery. We also assessed the 
proportion of patients meeting the glycaemic control criteria for the American Diabetes 
Association (ADA) and the International Diabetes Federation (IDF) criteria for optimisation 
of metabolic state after bariatric surgery(11, 15). We also assessed the frequency of weight re-
gain following achieving nadir weight following LAGB and assessed the relationship between 
glycaemic control and weight regain using the independent t test or the Mann-Whitney U 
test depending on data distribution. Statistical significance was defined as p<0.05.  
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 Results 
A total of 200 patients with obesity were included in the analysis, mostly middle-age 
women. Mean length of follow-up for weight was 62.0±13.0 months (range 18-84months), 
67.2±13.3 months (range 12-96 months) for HbA1C, 59.6±8.3 months (range 24-84months) 
for BP, 48.2±22.0 months (range 6-96months) for triglycerides and 61.70±19.30 months 
(range 12-96months) for total cholesterol. Baseline characteristics are summarised in table 
1.   Weight loss (figure 1a) 
LAGB resulted in progressive weight loss during the follow-up period with almost 70% of the 
total weight loss occurring in the first year. At one year mean total weight loss was  
14.9±22.5% (26.3±15.4kg), mean BMI loss was 9.2±5.3kg/m2 and mean excess BMI loss was 
34.0±17.6% with further reduction in weight by the end of the follow-up (Table 2,figure 1). A 
small proportion of patients (5/200) failed to lose any weight in the first 12 months; 
however there were only 2/192 patients who failed to demonstrate weight loss at the end 
of year 4. A weight loss nadir was achieved at 41.2±15.8 months, with only 3.5% and 0.5% of 
patients regaining more than 25% and 50% of their weight loss respectively. 8% of patients 
lost less than 10% of their weight, while 92% of patients maintained more than 10% weight 
loss, 76.6% lost more than 15% of their weight and 61% lost more than 20% of their weight 
at latest follow-up. 
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 Glycosylated Haemoglobin (figure 1b) 
HbA1c decreased progressively following LAGB from 7.9±1.9% (62.8 mmol/mol) pre-
operatively to 6.5±1.6% (47.5 mmol/mol) by study-end (Table 2). The improvements in 
HbA1c occurred despite a reduction in the number of patients requiring insulin treatment 
and insulin dosages (Figure 2). Information regarding the amount of oral metformin taken 
by each patient was also recorded. The mean dose was 1931 mg pre-operatively falling to 
1534 mg at the end of the study period. The number of patients on metformin reduced from 
147 pre-operatively to 31 patients at the end of the study. There were 8.6% of patients with 
a HbA1c <6% (42.1 mmol/mol) pre-operatively increasing to 40.7% by study-end.  
 
HbA1c improvements expressed as quartiles (quartile 1:≤-2.4%, quartile 2: -2.39 to -1.3%, 
quartile 3: -1.29 to -0.30%, quartile 4:≥-0.29%) revealed that final HbA1c across the quartiles 
were 6.1± 1.2%, 6.2 ± 1.5%, 6.2±1.2% and 7.8±1.8% for 1st, 2nd, 3rd and 4th quartile 
respectively. The associated weight loss associated with the quartiles of HbA1c changes 
were 23.0±11.2%, 25.4±13.3%, 23.7%±11.7% and 22.4±12.7% for quartiles 1-4 respectively 
(p=0.7 for the trend). Change in HbA1c did not differ between those who stopped insulin vs. 
patients who continued insulin treatment (-1.5±2.0% vs. -1.4±2.4%, p= 0.93). Similarly, there 
was no difference in HbA1c change between patients who regained ≥10% following nadir 
weight post LAGB and patients who did not regain weight (-1.4±2.8 vs. -1.4±1.9, p=0.83). 
 Blood pressure (figure 1c, d)  
Following LAGB there was significant reduction in systolic and diastolic BP (Table 2). Most of 
the decrease in systolic BP occurred in the first year which was maintained during follow-up. 
Similarly, the decrease in diastolic BP was mostly in the first year. The proportion of patients 
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who had a BP <130/80mmHg at baseline was 17.7% (33/186) increased by study-end to 
31.7% (52/164).  
 Lipids (figure 1e, f) 
Total cholesterol and triglycerides levels improved modestly by the end of the follow-up 
(Table 2). The improvements in total cholesterol occurred from year 3 post LAGB. 
Triglycerides levels improved within the first year post LAGB.  The percentage of patients 
achieving a total cholesterol levels <150mg/dl or 4mmol/l increased from 28.5% 
preoperatively to 32.0%, 30.8%, 36.5% and 35.0% at the end of years 1,2,3, and 4 
respectively.   Predictors of changes in metabolic parameters 
A summary of the linear regression analysis assessing the predictors of the change in HbA1c, 
BP and lipids can be found in Table 3 (below). Pre-operative BMI was not a significant 
predictor to changes in any of the metabolic parameters. Changes in weight were also not a 
predictor to any of the changes in metabolic parameters except diastolic BP. When 
percentage weight loss was assessed in quartiles (quartile1:≤-29.6%, quartile 2:-29.59 to -
23.78%, quartile 3:-23.77 to -15.83%, quartile 4:≥-15.82%), there was no difference in HbA1c 
changes from baseline across the weight loss quartiles (-1.50 ±1.6%, -1.7±2.2%, -1.1±1.7%, -
1.5±2.5%, p=0.64 using ANOVA and p=0.29 using Kruskal-Wallis test). 
 
Lower pre-operative HbA1c, pre-operative insulin treatment and older age were associated 
with less change in HbA1c with all levels of weight loss after LAGB. For systolic BP the main 
predictor was pre-operative systolic BP values with higher pre-operative systolic BP 
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associated with greater decreases in BP for all levels of weight loss after LAGB. Greater 
weight loss was associated with greater decreases in diastolic BP after LAGB. Greater 
improvements in HbA1c were also associated with greater improvements in total 
cholesterol and triglycerides levels for all levels of weight loss after LAGB. Higher pre-
operative total cholesterol and triglyceride levels were associated with greater reduction in 
their respective levels after LAGB. 
 Safety and surgical complications 
At 2 years post LAGB, there was no mortality and the mean length of stay was 1.3±3.4 days 
(range 0-49 days) with overall operative complication rate was 1% (2 patients had the band 
removed due to slippage).  
 
We attempted to contact all patients in 2013 but only managed to make successful contact 
in 100 patients (out of 200). Out of 100 patients, 88 still had the band in-situ by 2013. In the 
remaining 12 patients, 3 patients were converted to Roux-en-Y gastric bypass (RYGB) and 9 
patients had the band removed due to complications such as erosions, infection, slippage, 
pouch dilatation, intractable vomiting or patient choice. In this subgroup of 100 patients 
there was no mortality, with an overall operative complication rate over the entire study 
duration of 21% (21 patients). These complications included eight punctured bands/tubes, 
three band infections, seven partial band slippages, one port site bleed, and two wound 
infections. They were all successfully treated, repaired or replaced as appropriate with no 
long-term consequences for patients. 
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 Sensitivity analysis 
Using the baseline observation carried forward, we have repeated the same analysis that we 
detailed in Table 2 and that did not change the findings that were presented in Table 2 
except for diastolic BP which did not reach significance (Table 4). We have performed 
another sensitivity analysis using the data of the 88 patients who we know still have the 
band and that did not change the findings except that changes in diastolic BP which did not 
reach significance.  
 Discussion 
This study showed that LAGB combined with post-operative multidisciplinary care was 
effective and safe in patients with T2DM and obesity resulting in significant improvements 
in weight, BP, lipids and HbA1c that was maintained after an average of 5 years follow-up. 
The significant improvement in metabolic parameters is likely to reflect the use of the LAGB 
as an adjunct to holistic care of patients with diabetes in addition to a highly experienced 
MDT of surgeons, dieticians, radiologists and physicians(16, 17).  
 
Previous RCTs showed that LAGB was superior to medical treatment and lifestyle 
intervention in patients with T2DM over a 1-3 year period(5, 18, 19). Our results reflect the use 
of LAGB in conjunction with input from an experienced MDT which extended the 
improvements in weight loss and glycaemic control at 5 years follow-up. This may explain 
why the HbA1c reductions in our study were greater than the longest RCT to date (3 years) 
despite having similar baseline HbA1c between both studies and a shorter diabetes duration 
in the RCT compared to our study. The weight loss we achieved was also greater compared 
to the RCT (25%vs.15%); nonetheless in our data the amount of weight loss was not a 
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predictor of change in HbA1c. This could be due to patients losing less weight still profiting 
from good multidisciplinary input into their diabetes treatment(17).  
 
The improvements in HbA1c and weight were progressive over the follow-up which is 
different from other studies showing peak response at 1-2 years post-LAGB(18, 20). This could 
be due to our differences in study population, and the study settings and follow-up 
protocols which integrated optimal LAGB with medical care.  
 
The decline in LAGB popularity is partly driven by reports of higher rate of long-term 
complications compared to other bariatric procedures and the need for revisional surgery in 
patients with LAGB. Lazzati et al reported on more than 50 000 patients who received LAGB 
and showed that 28% had band removal at 5 years(21). In our study 12 of the 100 patients 
that were contactable in 2013 underwent revisional surgery or had band removal within the 
average 5 years follow-up. Such discrepancy can be explained by inter-centre differences in 
expertise and in technological advances in the band. In fact, Lazzati et al showed that there 
was a significant “centre” effect on band survival (Adjusted HR 0.79, 95%CI 0.7–0.89, p 
<0.001; HR were for band removal for centres that perform > 50 bands/year vs. <= 50 per 
year)(21) . Another longitudinal study showed that the need for revisional procedures in 
LAGB patients declined as the technique evolved (40% revision rate for proximal gastric 
enlargements in the first 10 years, vs. 6.4% in the past 5 years)(22). Our centre has 
longstanding experience providing LAGB for patients with morbid obesity for the last 16 
years which resulted in the developments of robust local surgical, medical, dietetic and 
radiological expertise.  
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Examining the predictor of metabolic outcomes in our study suggests that pre-operative 
factors such as higher HbA1c levels, or higher BMI or diabetes duration should not be 
barriers to patients undergoing LAGB as they do not predict worse outcomes, especially 
when LAGB is being combined with multidisciplinary input. Even the use of insulin which 
was associated with less post-LAGB HbA1c reductions should not be considered a barrier to 
receiving LAGB as many of these patients became insulin-free during the follow-up or there 
were significant reductions in insulin requirements.  
 
These observations raised the question of how many of our patients were interested in 
long-term weight loss maintenance as a primary treatment to improve their glycaemic and 
metabolic control and how many wanted weight loss for other reasons. Our study did not 
prospectively capture this information, but 36.2% of our patients pre-surgery would have 
been considered to have good glycaemic control (HbA1c<7% (53.0 mmol/mol)) and 30.3% to 
have poor glycaemic control (HbA1c≥8.5% (69.4 mmol/mol)). After surgery 69% satisfied the 
ADA criteria for good glycaemic control (HbA1c<7% (53.0 mmol/mol)) and 42.7% achieved a 
HbA1c<6% (42.1 mmol/mol). However, only 10.3% met all the criteria of the IDF to signal 
optimal metabolic control when considering weight loss, glycaemic control, BP control and 
control of dyslipidaemia(23). These results with LAGB are similar to groups who used other 
bariatric procedures(15), suggesting that despite our integration of LAGB with a dedicated 
team providing multidisciplinary input, more can be done with the optimal use of 
medication to get even better control of weight, glycaemic control, high BP and 
dyslipidaemia.    
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The design of this study does not to differentiate the effects of LAGB from medical care due 
to the lack of control arm. However, our results show the benefits of such combined 
approach in real life. Despite, loss of follow-up we still had an average follow-up of 5 years 
with more than 80% of patients having data for most study parameters and the sensitivity 
analysis did not change our findings.  There is also inherent selection bias for patients who 
specifically chose LAGB as opposed to alternative procedures or no procedures. Another 
limitation of this study is the lack of data regarding the use of oral hypoglycaemic, anti-
hypertensives and lipid lowering treatments during the follow-up, but nonetheless it was 
clear that the metabolic improvements occurred in the context of less insulin usage. Our 
findings showed that LAGB combined with multidisciplinary care resulted in significant 
weight loss and improvements in HbA1c despite the less use of insulin and metformin after 
LAGB. The improvements observed in BP and lipids can be related to the use of 
pharmacotherapy as data regarding BP and lipid lowering medications are not available in 
this trial. However, this is unlikely to be the case as weight loss has been shown in previous 
trials to result in improvements in BP and lipids(24) and previous RCTs showed the favourable 
impact of LAGB on BP and lipids(5). We also only managed to successfully contact 100 out of 
200 patients to ensure that they still have the band but the sensitivity analysis including the 
88 patients who we know that still have the band in situ showed similar results to the total 
study population.  
 
The study also has its strengths including the long follow-up duration and high retention 
rate in relation to patient’s metabolic data.  The LAGB and post-LAGB care were performed 
in an experienced surgical centre with a good set up for LAGB which was integrated with 
state of the art MDT.  
16 
 
 
In conclusion, weight loss after LAGB combined with multidisciplinary input is helpful to 
patients with obesity and T2DM and result in significant improvements to glycaemic control 
and multiple cardiovascular disease risk factors over 5 years period. Pre-operative BMI and 
diabetes duration did not predict changes in HbA1c, BP or lipids following LAGB in the 
context of multidisciplinary care following the LAGB.  
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Number of patients 200 
Age (years) 47 (9.7; 25 - 74) 
Gender (male/female) 77/123 
Duration of diabetes (months) 82.8 (14.0; 53.8 - 127.3) 
Pre-operative weight (Kg) 150.3 (29.8; 93 - 240) 
Pre-operative BMI (Kg/m2) 52.8 (9.2; 35.9 - 81.8) 
HbA1c (%) (185 patients) 7.9 (1.9; 3.7 - 13.3) 
Systolic BP (mmHg) 140.3 (17.7; 140 - 196) 
Diastolic BP (mmHg) 96.0 (10.9; 90 - 114) 
Hypertension (known hypertension or SBP≥140 
or DBP≥90 or both) (186 patients) 
104(55.9%)  
                                         
Drug treatment:  
Insulin number (%) 71 (35.5) 
Metformin number (%) 147 (73.5) 
 
Table 1. Baseline demographics for the study population.  Data presented as mean (standard 
deviation; range) or n (frequency). BMI - body mass index, HbA1c - glycosylated haemoglobin, BP - 
systolic blood pressure, BP - diastolic blood pressure. 
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 Baseline No. Of 
patients 
(%) 
1 year No. Of 
patients 
(%) 
Latest 
time-
point 
No. of 
patients 
(%) 
P value* 
HbA1c (%) 7.9 ± 1.9 185 (92.5) 7.1 ± 1.7 160 (80) 6.5 ± 1.6 170 (85.5) <0.001 
Weight (kg) 150.3 ± 
29.8 
200 (100) 124.3 ± 
27.8 
195 (97.5) 112.8 ± 
25.7 
200 (100) <0.001 
Systolic BP 
(mmHg) 
140.1 ± 
17.7 
186 (93) 129.2 ± 
13.5 
179 (89.5) 126.9 ± 
9.6 
183 (91.5) <0.001 
Diastolic BP 
(mmHg) 
82.2 ± 
10.8 
186 (93) 77.9 ± 8.6 179 (89.5) 79.7 ± 5.3 183 (91.5) 0.007 
Total 
cholesterol 
(mmol/l) 
4.6 ± 1.1 179 (89.5) 4.6 ± 1.0 166 (83) 4.2 ± 1.1 169 (84.5) 0.006 
Triglycerides 
(mmol/l) 
2.0 ± 1.0 157 (78.5) 1.8 ± 1.0 139 (69.5) 1.5 ± 0.7 133 (66.5) <0.001 
 
Table 2. Changes in metabolic parameters from baseline to final available reading. Data presented as 
mean ± standard deviation. *p-value paired t-test between baseline and latest value available. 
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Outcome measure Variable B value P value 
Change in HbA1C 
R2 = 0.470 
Pre-op HbA1c -0.694 <0.001  
Insulin therapy 0.682 0.007 
Age 0.023 0.037 
Gender MF -0.299 0.156 
Diabetes duration 0.003 0.112 
% change in weight 0.008 0.359 
Pre-op BMI -0.005 0.710 
Change in Systolic BP 
R2 = 0.758 
Age 0.066 0.425 
Gender MF 2.777 0.082 
Diabetes duration 0.012 0.348 
% change in weight 0.069 0.299 
Pre-op BMI 0.026 0.780 
Pre-op HbA1c 0.936 0.101 
Change in HbA1c 0.993 0.090 
Pre- op Systolic BP -0.869 <0.001 
Change in diastolic BP 
R2 = 0.820 
Pre-op Diastolic BP -0.941 <0.001 
Age  -0.057 0.218 
Gender MF 2.096 0.016 
Diabetes duration 0.005 0.458 
%change in weight 0.089 0.015 
Pre-op BMI 0.008 0.871 
Pre-op HbA1c -0.217 0.487 
Change in HbA1c -0.191 0.546 
Change in cholesterol 
R2 = 0.367 
Age -0.012 0.167 
Gender MF -0.123 0.459 
Diabetes duration 0.000 0.916 
% change in weight 0.003 0.667 
Pre-op BMI 0.008 0.425 
Pre-op HbA1c 0.052 0.399 
Change in HbA1c 0.165 0.009 
Pre-op cholesterol -0.582 <0.001 
Change in triglyceride  
R2 = 0.556 
Age -0.012 0.055 
Gender MF 0.102 0.386 
Diabetes duration 0.000 0.638 
%change in weight 0.005 0.244 
Pre-op BMI 0.006 0.400 
Pre-op HbA1c 0.086 0.044 
Change in HbA1c 0.059 0.179 
Pre-op triglyceride -0.601 <0.001 
 
Table 3. Predictors of changes in metabolic parameters using linear regression. Change in 
each variable was calculated as study end value - baseline value. BP: blood pressure; BMI: 
body mass index, MF: male/female. 
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Figure 1. Changes in each variable over the follow up period. Error bar represent standard error and 
numbers in brackets indicate the number of patient for which data was available at each time point. 
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Figure 2. (a) The proportion of the 71 patients who were on insulin at the start of the study period 
who subsequently discontinued therapy by the end of year 4. (b) Changes in the mean insulin dose 
of patients still on this medication up to five years from baseline. Numbers in brackets indicate 
number of patients at the end of each year. Error bars represent standard error.  
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(b) Insulin requirements 
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 Baseline No. Of 
patients (%) 
Latest time-
point 
No. of 
patients (%) 
P value* 
HbA1c (%) 7.7 ± 1.9 74 (84.1) 6.3 ± 1.6 74 (84.1) 0.000 
Weight (kg) 145.9 ± 27.6 79 (89.8) 112.0 ± 
26.9 
79 (89.8) 0.000 
Systolic BP 
(mmHg) 
138.7 ± 16.2 74 (84.1) 126.8 ± 
11.5 
74 (84.1) 0.000 
Diastolic BP 
(mmHg) 
81.7 ± 9.0 74 (84.1) 79.7 ± 5.6 74 (84.1) 0.094 
Total 
cholesterol 
(mmol/l) 
4.6 ± 1.1 67 (76.1) 4.2 ± 1.0 67 (76.1) 0.004 
Triglycerides 
(mmol/l) 
1.8 ± 0.6 62 (70.5) 1.5 ± 0.6 62 (70.5) 0.001 
 
Table 4. Changes in metabolic parameters from baseline to final available reading for the 88 patients 
who still had their band in situ. Data presented as mean ± standard deviation. *p-value paired t-test 
between baseline and latest value available. 
 
